Dong-A to receive $17 million in royalties from Trius Therapeutics

Published: 2008-09-29 06:47:00

Updated: 2008-09-29 06:47:00

Trius Therapeutics, U.S. based pharmaceutical company, is to pay some $17 million in royalties for the development of Dong-A’s new second generation oral and IV oxazolidinone antibiotic (DA-7218), as Trius Therapeutics, Inc. announced on September 22 the initiation of Phase 2 testing for DA-7218.

The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.